موافقات الدواء

Myelodysplastic Syndromes (MDS)
Azacitidine is indicated for treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
Juvenile Myelomonocytic Leukemia (JMML)
Azacitidine is indicated for the treatment of pediatric patients aged one month and older with newly diagnosed JMML